Adma Biologics reported $34.91M in Cash and Equivalent for its third fiscal quarter of 2022.

Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
Cash And Equivalent Change
Adamis Pharmaceuticals ADMP:US USD 2.42M 6.46M
Adma Biologics ADMA:US USD 34.91M 17.51M
Agile Therapeutics AGRX:US USD 6.14M 6.88M
Alnylam Pharmaceuticals ALNY:US USD 1.07B 497.67M
Biocryst Pharmaceuticals BCRX:US USD 461.19M 43.71M
Dynavax Technologies DVAX:US USD 586.49M 337.4M
Minerva Neurosciences NERV:US USD 40.22M 9.53M
Novavax NVAX:US USD 1.28B 95.01M
Omeros OMER:US USD 145.53M 131.4M
Takeda 4502:JP JPY 798.14B 152.15B